| | | | Join us for the next Faculty Seminar on March 1st
The Cancer Center at Illinois has exciting new faculty presentations planned for Spring 2018. Registration is recommended, as seats are limited. Make plans now to attend!
- March 1, 2018; 3–4:30 p.m., Beckman Institute, Room 3269
Roy Dar, Assistant Professor, Bioengineering
“Engineering Fluctuations in Gene Expression for Biasing Cell-Fate Decisions”
Dipanjan Pan, Associate Professor, Bioengineering
“In Silico to In Vivo Molecularly Targeted Imaging and Therapy for Liver Cancer”
Paul Hergenrother, Professor, Chemistry
“Traversing the Valley of Death in Anticancer Drug Discovery"
- April Seminar: April 5, 2018; 3–4:30 p.m., Beckman Institute, Room 4269
- May Seminar: May 3, 2018; 3–4:30 p.m., Beckman Institute, Room 3269
|
|
Carle Cancer Research Update Meetings Join the discussion at the Carle Cancer Research Update Meeting. Lunch is not served, but you are welcome to bring your own lunch.
Topic: “Assessing Malnutrition in the Clinical Setting”
Speaker: Kirsten Harold, University of Illinois Dietetic Intern
Date: Friday, February 8, 2018, Noon – 12:30 p.m.
Location: Houseworth Conference Room
Carle Cancer Center/MBCI – Second Floor
*Following are the instructions on how to join the Live Meeting by phone*
Dial-in Number: 1(872) 395-5961
Conference ID: 27407746
Sponsored by the Carle Cancer Center |
|
 | | | The pixelated spatial gene expression tool can analyze an entire tissue sample and identify cancer cells in a process that takes less than two hours. | | | |
Special Delivery: Nano-Size Particles Carry Personalized Medicinces Scientists at the Sloan Kettering Institute have developed a machine-learning approach to building personalized cancer nanomedicines. These tiny drug-filled particles help cancer medicines hit their target, making them more effective and causing fewer side effects. Learn more… |
|
Selective enhancer changes in osteosarcoma lung metastasis A recent study investigates the contribution of epigenomic plasticity to lung metastasis in osteosarcoma. Changes in the enhancer landscape were found to be nonrandom and driven by selective forces in the microenvironment. Learn more… |
|
Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance Investigators report a lipid membrane-coated silica-carbon (LSC) hybrid nanoparticle that targets mitochondria through pyruvate, to specifically produce reactive oxygen species (ROS) in mitochondria under near-infrared (NIR) laser irradiation. Learn more… |
|
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. Learn more… |
|
Early Detection of Ovarian Cancer Award: $50,000
Due: March 1, 2018 @ 4:00 PM CST
The Minnesota Ovarian Cancer Alliance is accepting proposals for research related to the early detection of cancer. MOCA will award one-year grans of up to $50,000 to support individual projects or a part of a larger research project related to early detection of ovarian, primary peritoneal, or fallopian tube cancer. Projects must be conducted outside the state of Minnesota. See the MOCA website for complete program guidelines and application instructions.
Contact the Office of Foundation Relations for:
- Editing assistance, strategy consultation, and general questions
- Background information about this foundation
MOCA RFP |
|
Cancer Prevention and Control Clinical Trials Grant Program Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications that include investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and the NCI Division of Cancer Control and Population Sciences as based on their scientific missions. Applications for clinical trials submitted under this FOA should be hypothesis-driven, have clearly described aims and objectives, and have the potential to reduce the burden of cancer through improvements in knowledge, early detection and diagnosis, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to positively impact clinical practice and/or public health. For more information... |
|
Early Phase Clinical Trials for Cancer Treatment and Diagnosis The purpose of this Funding Opportunity Announcement (FOA) is to solicit research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials of relevance to the research mission of the National Cancer Institutes (NCI) Division of Cancer Treatment and Diagnosis (DCTD) programs. Applicants are strongly encouraged to consult the DCTD website, https://dctd.cancer.gov/, to learn more about the various program goals, research priorities and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. For more information... |
|
NCI accepting applications for transdisciplinary research leveraging cognitive neuroscience to improve measurement of cognitive impairment following cancer treatment With this Funding Opportunity Announcement, the National Cancer Institute (NCI) invites applications for Research Project (R01) applications. This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans. For more information ...
This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information. This FOA runs in parallel with an FOA of similar scientific scope, PAR-18-605, which utilizes the Research Project Grant (R01) mechanism. For more information… |
|
For more information, visit our website at cancer.illinois.edu.
If you received an award or honor, published a paper, have an announcement and/or news to share, we want to hear from you. Send your success stories/news items to Margaret Browne Huntt, Associate Director, by the end of business on Tuesday of each week.
Visit the Cancer Center Events Calendar for a complete list of upcoming cancer-related activities and events. |
|
|
| |
| |
|
